person · Reporting owner

Murray Mark J.

Disclosed activity across 1 company

Tapewire entity: 159467
SEC CIK: 0001628383

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arbutus Biopharma CorpABUS · Entity 4953	Director · President and CEO	March 01, 2019	March 05, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arbutus Biopharma Corp

Report date March 01, 2019 · Filed March 05, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.57 · Expires 2029-03-01	Direct	357,500	Reported balance After 2019-03-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-03-01 · Grant · Acquired 357,500 · Balance 357,500 F1: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 01, 2019 Filed Mar 5, 2019 23:07 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantEmployee Stock Option (Right to Buy) · Derivative	357,500	$0.00 Strike: $4.57	$0.00	Disclosure SEC source: 0001123292-19-000435 · edgar.xml · derivative · entry 1 Murray Mark J. · CIK 0001628383 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,500 Underlying: Common Shares · 357,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: The option will vest and become exercisable in three equal annual installments beginning March 1, 2020. Read SEC document
November 28, 2018 Filed Nov 30, 2018 21:55 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.35	$0.00	Disclosure SEC source: 0001123292-18-001091 · edgar.xml · derivative · entry 2 Murray Mark J. · CIK 0001628383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,000 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted from an exercise price of C$1.80 based on a conversion rate of C$1.33:$1.00 as of November 28, 2018. F2 · derivative.exercise_date: The option vested 1/4 on December 8, 2008, with the remaining portion vesting in equal annual installments beginning on December 8, 2009. Read SEC document
November 28, 2018 Filed Nov 30, 2018 21:55 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	Exercise / conversionCommon Shares	25,000	$1.35	$33,750.00	Disclosure SEC source: 0001123292-18-001091 · edgar.xml · nonDerivative · entry 1 Murray Mark J. · CIK 0001628383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted from an exercise price of C$1.80 based on a conversion rate of C$1.33:$1.00 as of November 28, 2018. Read SEC document
April 17, 2018 Filed Apr 18, 2018 00:22 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	27,007	$0.00 Strike: $0.35	$0.00	Disclosure SEC source: 0001140361-18-018863 · doc1.xml · derivative · entry 3 Murray Mark J. · CIK 0001628383 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,007 shares Expires 2018-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from Canadian exercise price of $0.4444; Cdn$1.2552=US$1.00. F3 · derivative.expiration_date: Expiration date extended through termination of blackout period. Read SEC document
April 17, 2018 Filed Apr 18, 2018 00:22 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	Exercise / conversionCommon Shares	27,007	$0.35	$9,560.48	Disclosure SEC source: 0001140361-18-018863 · doc1.xml · nonDerivative · entry 1 Murray Mark J. · CIK 0001628383 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Converted from Canadian exercise price of $0.4444; Cdn$1.2552=US$1.00. Read SEC document
April 16, 2018 Filed Apr 18, 2018 00:22 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantEmployee Stock Option (Right to Buy) · Derivative	418,187	$0.00 Strike: $5.20	$0.00	Disclosure SEC source: 0001140361-18-018863 · doc1.xml · derivative · entry 2 Murray Mark J. · CIK 0001628383 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,187 Underlying: Common Stock · 418,187 shares Expires 2028-04-16 F1 · derivative.exercise_date: The options vest as follows: 1/3 on April 16, 2019; 1/3 on April 16, 2020; and 1/3 on April 16, 2021. Read SEC document
March 24, 2017 Filed Apr 5, 2017 19:43 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantEmployee Stock Option (Right to Buy) · Derivative	450,000	$0.00 Strike: $3.15	$0.00	Disclosure SEC source: 0001140361-17-014883 · doc1.xml · derivative · entry 1 Murray Mark J. · CIK 0001628383 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-03-24 F1 · derivative.exercise_date: The options vest as follows: 1/3 on March 23, 2018; 1/3 on March 23, 2019; 1/3 on March 23, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.